Regulatory factors of ILC2 are therapeutic targets for lung inflammation

Kubo M. Innate and adaptive type 2 immunity in lung allergic inflammation. Immunol Rev. 2017;278(1):162–72. https://doi.org/10.1111/imr.12557

Gurram RK, Zhu J. Orchestration between ILC2s and Th2 cells in shaping type 2 immune responses. Cell Mol Immunol. 2019;16(3):225–35. https://doi.org/10.1038/s41423-019-0210-8

Canani RB, Costanzo MD, Leone L, Pedata M, Meli R, Calignano A. Potential beneficial effects of butyrate in intestinal and extraintestinal diseases. World J Gastroenterol. 2011;17(12):1519–28. https://doi.org/10.3748/wjg.v17.i12.1519

Zheng C, Lu Z, Wu H, Cui L, Bi J, Wan X. Exogenous oxidative stress suppresses IL‐33‐driven proliferation programming in group 2 innate lymphoid cells. Int Immunopharm. 2021;95:107541. https://doi.org/10.1016/j.intimp.2021.107541

Darby IA, Hewitson TD. Hypoxia in tissue repair and fibrosis. Cell Tissue Res. 2016;365(3):553–62. https://doi.org/10.1007/s00441-016-2461-3

Lee JW, Ko J, Ju C, Eltzschig HK. Hypoxia signaling in human diseases and therapeutic targets. Exp Mol Med. 2019;51(6):1–13. https://doi.org/10.1038/s12276-019-0235-1

Takami D, Abe S, Shimba A, Asahi T, Cui G, Tani‐ichi S, et al. Lung group 2 innate lymphoid cells differentially depend on local IL‐7 for their distribution, activation, and maintenance in innate and adaptive immunity‐mediated airway inflammation. Int Immunol. 2023;35(11):513–30. https://doi.org/10.1093/intimm/dxad029

Artis D, Spits H. The biology of innate lymphoid cells. Nature. 2015;517(7534):293–301. https://doi.org/10.1038/nature14189

Mariotti FR, Quatrini L, Munari E, Vacca P, Moretta L. Innate lymphoid cells: expression of PD‐1 and other checkpoints in normal and pathological conditions. Front Immunol. 2019;10:910. https://doi.org/10.3389/fimmu.2019.00910

Vivier E, Artis D, Colonna M, Diefenbach A, Di Santo JP, Eberl G, et al. Innate lymphoid cells: 10 Years on. Cell. 2018;174(5):1054–66. https://doi.org/10.1016/j.cell.2018.07.017

Duerr CU, Fritz JH. Regulation of group 2 innate lymphoid cells. Cytokine. 2016;87:1–8. https://doi.org/10.1016/j.cyto.2016.01.018

Camelo A, Rosignoli G, Ohne Y, Stewart RA, Overed‐Sayer C, Sleeman MA, et al. IL‐33, IL‐25, and TSLP induce a distinct phenotypic and activation profile in human type 2 innate lymphoid cells. Blood Adv. 2017;1(10):577–89. https://doi.org/10.1182/bloodadvances.2016002352

Matsuyama T, Salter BM, Emami Fard N, Machida K, Sehmi R. TNF superfamily and ILC2 activation in asthma. Biomolecules. 2024;14(3):294. https://doi.org/10.3390/biom14030294

Wallrapp A, Burkett PR, Riesenfeld SJ, Kim SJ, Christian E, Abdulnour REE, et al. Calcitonin gene‐related peptide negatively regulates alarmin‐driven type 2 innate lymphoid cell responses. Immunity. 2019;51(4):709–23.e6. https://doi.org/10.1016/j.immuni.2019.09.005

Nagashima H, Mahlakõiv T, Shih HY, Davis FP, Meylan F, Huang Y, et al. Neuropeptide CGRP limits group 2 innate lymphoid cell responses and constrains type 2 inflammation. Immunity. 2019;51(4):682–95.e6. https://doi.org/10.1016/j.immuni.2019.06.009

Xu H, Ding J, Porter CBM, Wallrapp A, Tabaka M, Ma S, et al. Transcriptional atlas of intestinal immune cells reveals that neuropeptide α‐CGRP modulates group 2 innate lymphoid cell responses. Immunity. 2019;51(4):696–708.e9. https://doi.org/10.1016/j.immuni.2019.09.004

Moriyama S, Brestoff JR, Flamar AL, Moeller JB, Klose CSN, Rankin LC, et al. β₂‐adrenergic receptor‐mediated negative regulation of group 2 innate lymphoid cell responses. Science. 2018;359(6379):1056–61. https://doi.org/10.1126/science.aan4829

Schmidt FM, Lichtblau N, Minkwitz J, Chittka T, Thormann J, Kirkby KC, et al. Cytokine levels in depressed and non‐depressed subjects, and masking effects of obesity. J Psychiatr Res. 2014;55:29–34. https://doi.org/10.1016/j.jpsychires.2014.04.021

Dahl J, Ormstad H, Aass HCD, Malt UF, Bendz LT, Sandvik L, et al. The plasma levels of various cytokines are increased during ongoing depression and are reduced to normal levels after recovery. Psychoneuroendocrinology. 2014;45:77–86. https://doi.org/10.1016/j.psyneuen.2014.03.019

Wang Z, Yan C, Du Q, Huang Y, Li X, Zeng D, et al. HTR2A agonists play a therapeutic role by restricting ILC2 activation in papain‐induced lung inflammation. Cell Mol Immunol. 2023;20(4):404–18. https://doi.org/10.1038/s41423-023-00982-6

Cao Y, Li Y, Wang X, Liu S, Zhang Y, Liu G, et al. Dopamine inhibits group 2 innate lymphoid cell‐driven allergic lung inflammation by dampening mitochondrial activity. Immunity. 2023;56(2):320–35.e9. https://doi.org/10.1016/j.immuni.2022.12.017

You C, Zhang Y, Xu P, Huang S, Yin W, Eric Xu H, et al. Structural insights into the peptide selectivity and activation of human neuromedin U receptors. Nat Commun. 2022;13(1):2045. https://doi.org/10.1038/s41467-022-29683-w

Wallrapp A, Riesenfeld SJ, Burkett PR, Abdulnour RE, Nyman J, Dionne D, et al. The neuropeptide NMU amplifies ILC2‐driven allergic lung inflammation. Nature. 2017;549(7672):351–6. https://doi.org/10.1038/nature24029

Malhi GS, Mann JJ. Depression. Lancet. 2018;392(10161):2299–312. https://doi.org/10.1016/S0140-6736(18)31948-2

Berger M, Gray JA, Roth BL. The expanded biology of serotonin. Annu Rev Med. 2009;60(1):355–66. https://doi.org/10.1146/annurev.med.60.042307.110802

Dürk T, Duerschmied D, Müller T, Grimm M, Reuter S, Vieira RP, et al. Production of serotonin by tryptophan hydroxylase 1 and release via platelets contribute to allergic airway inflammation. Am J Respir Crit Care Med. 2013;187(5):476–85. https://doi.org/10.1164/rccm.201208-1440OC

Cosmi L, Liotta F, Maggi L, Annunziato F. Role of type 2 innate lymphoid cells in allergic diseases. Curr Allergy Asthma Rep. 2017;17(10):66. https://doi.org/10.1007/s11882-017-0735-9

Karagiannis F, Masouleh SK, Wunderling K, Surendar J, Schmitt V, Kazakov A, et al. Lipid‐droplet formation drives pathogenic group 2 innate lymphoid cells in airway inflammation. Immunity. 2020;52(4):620–34.e6. https://doi.org/10.1016/j.immuni.2020.03.003

Sato H, Taketomi Y, Ushida A, Isogai Y, Kojima T, Hirabayashi T, et al. The adipocyte‐inducible secreted phospholipases PLA2G5 and PLA2G2E play distinct roles in obesity. Cell Metabol. 2014;20(1):119–32. https://doi.org/10.1016/j.cmet.2014.05.002

Singer AG, Ghomashchi F, Le Calvez C, Bollinger J, Bezzine S, Rouault M, et al. Interfacial kinetic and binding properties of the complete set of human and mouse groups Ⅰ, Ⅱ, Ⅴ, Ⅹ, and Ⅻ secreted phospholipases A2. J Biol Chem. 2002;277(50):48535–49. https://doi.org/10.1074/jbc.M205855200

Giannattasio G, Fujioka D, Xing W, Katz HR, Boyce JA, Balestrieri B. Group V secretory phospholipase A2 reveals its role in house dust mite‐induced allergic pulmonary inflammation by regulation of dendritic cell function. J Immunol. 2010;185(7):4430–8. https://doi.org/10.4049/jimmunol.1001384

Ohta S, Imamura M, Xing W, Boyce JA, Balestrieri B. Group V secretory phospholipase A2 is involved in macrophage activation and is sufficient for macrophage effector functions in allergic pulmonary inflammation. J Immunol. 2013;190(12):5927–38. https://doi.org/10.4049/jimmunol.1203202

Yamaguchi M, Zacharia J, Laidlaw TM, Balestrieri B. PLA2G5 regulates transglutaminase activity of human IL‐4‐activated M2 macrophages through PGE2 generation. J Leukoc Biol. 2016;100(1):131–41. https://doi.org/10.1189/jlb.3A0815-372R

Muñoz NM, Meliton AY, Arm JP, Bonventre JV, Cho W, Leff AR. Deletion of secretory group V phospholipase A2 attenuates cell migration and airway hyperresponsiveness in immunosensitized mice. J Immunol. 2007;179(7):4800–7. https://doi.org/10.4049/jimmunol.179.7.4800

Doherty TA, Khorram N, Lund S, Mehta AK, Croft M, Broide DH. Lung type 2 innate lymphoid cells express Cysteinyl leukotriene receptor 1, which regulates TH2 cytokine production. J Allergy Clin Immunol. 2013;132(1):205–13. https://doi.org/10.1016/j.jaci.2013.03.048

Wojno ED, Monticelli LA, Tran SV, Alenghat T, Osborne LC, Thome JJ, et al. The prostaglandin D₂ receptor CRTH2 regulates accumulation of group 2 innate lymphoid cells in the inflamed lung. Mucosal Immunol. 2015;8(6):1313–23. https://doi.org/10.1038/mi.2015.21

Yamaguchi M, Samuchiwal SK, Quehenberger O, Boyce JA, Balestrieri B. Macrophages regulate lung ILC2 activation via Pla2g5‐dependent mechanisms. Mucosal Immunol. 2018;11(3):615–26. https://doi.org/10.1038/mi.2017.99

Dixon RA, Diehl RE, Opas E, Rands E, Vickers PJ, Evans JF, et al. Requirement of a 5‐lipoxygenase‐activating protein for leukotriene synthesis. Nature. 1990;343(6255):282–4. https://doi.org/10.1038/343282a0

Reid GK, Kargman S, Vickers PJ, Mancini JA, Léveillé C, Ethier D, et al. Correlation between expression of 5‐lipoxygenase‐activating protein, 5‐lipoxygenase, and cellular leukotriene synthesis. J Biol Chem. 1990;265(32):19818–23. https://doi.org/10.1016/s0021-9258(17)45446-9

Kanaoka Y, Boyce JA. Cysteinyl leukotrienes and their receptors: cellular distribution and function in immune and inflammatory responses. J Immunol. 2004;173(3):1503–10. https://doi.org/10.4049/jimmunol.173.3.1503

Lund SJ, Portillo A, Cavagnero K, Baum RE, Naji LH, Badrani JH, et al. Leukotriene C4 potentiates IL‐33‐induced group 2 innate lymphoid cell activation and lung inflammation. J Immunol. 2017;199(3):1096–104. https://doi.org/10.4049/jimmunol.1601569

Krishnamoorthy N, Burkett PR, Dalli J, Abdulnour REE, Colas R, Ramon S, et al. Cutting edge: maresin‐1 engages regulatory T cells to limit type 2 innate lymphoid cell activation and promote resolution of lung inflammation. J Immunol. 2015;194(3):863–7. https://doi.org/10.4049/jimmunol.1402534

Machado‐Carvalho L, Roca‐Ferrer J, Picado C. Prostaglandin E2 receptors in asthma and in chronic rhinosinusitis/nasal polyps with and without aspirin hypersensitivity. Respir Res. 2014;15(1):100. https://doi.org/10.1186/s12931-014-0100-7

Maric J, Ravindran A, Mazzurana L, Björklund ÅK, Van Acker A, Rao A, et al. Prostaglandin E₂ suppresses human group 2 innate lymphoid cell function. J Allergy Clin Immunol. 2018;141(5):1761–73.e6. https://doi.org/10.1016/j.jaci.2017.09.050

Sreeramkumar V, Fresno M, Cuesta N. Prostaglandin E2 and T cells: friends or foes? Immunol Cell Biol. 2012;90(6):579–86. https://doi.org/10.1038/icb.2011.75

Konya V, Üllen A, Kampitsch N, Theiler A, Philipose S, Parzmair GP, et al. Endothelial E‐type prostanoid 4 receptors promote barrier function and inhibit neutrophil trafficking. J Allergy Clin Immunol. 2013;131(2):532–40. e1–2. https://doi.org/10.1016/j.jaci.2012.05.008

Luschnig‐Schratl P, Sturm EM, Konya V, Philipose S, Marsche G, Fröhlich E, et al. EP4 receptor stimulation down‐regulates human eosinophil function. Cell Mol Life Sci. 2011;68(21):3573–87. https://doi.org/10.1007/s00018-011-0642-5

MacKenzie KF, Clark K, Naqvi S, McGuire VA, Nöehren G, Kristariyanto Y, et al. PGE(2) induces macrophage IL‐10 production and a regulatory‐like phenotype via a protein kinase A‐SIK‐CRTC3 pathway. J Immunol. 2013;190(2):565–77. https://doi.org/10.4049/jimmunol.1202462

McNabney SM, Henagan TM. Short chain fatty acids in the colon and peripheral tissues: a focus on butyrate, colon cancer, obesity and insulin resistance. Nutrients. 2017;9(12):1348. https://doi.org/10.3390/nu9121348

Lewis G, Wang B, Shafiei Jahani P, Hurrell BP, Banie H, Aleman Muench GR, et al. Dietary fiber‐induced microbial Short chain fatty acids suppress ILC2‐dependent airway inflammation. Front Immunol. 2019;10:2051. https://doi.org/10.3389/fimmu.2019.02051

Rao DM, Phan DT, Choo MJ, Weaver MR, Oberley‐Deegan RE, Bowler RP, et al. Impact of fatty acid binding protein 5‐deficiency on COPD exacerbations and cigarette smoke‐induced inflammatory response to bacterial infection. Clin Transl Med. 2019;8(1):7. https://doi.org/10.1186/s40169-019-0227-8

Moore SM, Holt VV, Malpass LR, Hines IN, Wheeler MD. Fatty acid‐binding protein 5 limits the anti‐inflammatory response in murine macrophages. Mol Immunol. 2015;67(2 Pt B):265–75. https://doi.org/10.1016/j.molimm.2015.06.001

Gally F, Chu HW, Bowler RP. Cigarette smoke decreases airway epithelial FABP5 expression and promotes Pseudomonas aeruginosa infection. PLoS One. 2013;8(1):e51784. https://doi.org/10.1371/journal.pone.0051784

Kobayashi S, Tayama S, Phung HT, Kagawa Y, Miyazaki H, Takahashi Y, et al. Fatty acid‐binding protein 5 limits ILC2‐mediated allergic lung inflammation in a murine asthma model. Sci Rep. 2020;10(1):16617. https://doi.org/10.1038/s41598-020-73935-y

Cekic C, Linden J. Purinergic regulation of the immune system. Nat Rev Immunol. 2016;16(3):177–92. https://doi.org/10.1038/nri.2016.4

Allard B, Allard D, Buisseret L, Stagg J. The adenosine pathway in immuno‐oncology. Nat Rev Clin Oncol. 2020;17(10):611–29. https://doi.org/10.1038/s41571-020-0382-2

Le TT, Berg NK, Harting MT, Li X, Eltzschig HK, Yuan X. Purinergic signaling in pulmonary inflammation. Front Immunol. 2019;10:1633. https://doi.org/10.3389/fimmu.2019.01633

Xiao Q, Han X, Liu G, Zhou D, Zhang L, He J, et al. Adenosine restrains ILC2‐driven allergic airway inflammation via A2A receptor. Mucosal Immunol. 2022;15(2):338–50. https://doi.org/10.1038/s41385-021-00475-7

Lu HC, Mackie K. An introduction to the endogenous cannabinoid system. Biol Psychiatr. 2016;79(7):516–25. https://doi.org/10.1016/j.biopsych.2015.07.028

Angelina A, Pérez‐Diego M, López‐Abente J, Palomares O. The role of cannabinoids in allergic diseases: collegium internationale allergologicum (CIA) update 2020. Int Arch Allergy Immunol. 2020;181(8):565–84. https://doi.org/10.1159/000508989

Hurrell BP, Helou DG, Shafiei‐Jahani P, Howard E, Painter JD, Quach C, et al. Cannabinoid receptor 2 engagement promotes group 2 innate lymphoid cell expansion and enhances airway hyperreactivity. J Allergy Clin Immunol. 2022;149(5):1628–42.e10. https://doi.org/10.1016/j.jaci.2021.09.037

Kanj AN, Kottom TJ, Schaefbauer KJ, Choudhury M, Limper AH, Skalski JH. Dysbiosis of the intestinal fungal microbiota increases lung resident group 2 innate lymphoid cells and is associated with enhanced asthma severity in mice and humans. Respir Res. 2023;24(1):144. https://doi.org/10.1186/s12931-023-02422-5

Wiesener MS, Jürgensen JS, Rosenberger C, Scholze CK, Hörstrup JH, Warnecke C, et al. Widespread hypoxia‐inducible expression of HIF‐2alpha in distinct cell populations of different organs. Faseb J. 2003;17(2):271–3. https://doi.org/10.1096/fj.02-0445fje

Han J, Wan Q, Seo GY, Kim K, El Baghdady S, Lee JH, et al. Hypoxia induces adrenomedullin from lung epithelia, stimulating ILC2 inflammation and immunity. J Exp Med. 2022;219(6):e20211985. https://doi.org/10.1084/jem.20211985

Daynes RA, Jones DC. Emerging roles of PPARs in inflammation and immunity. Nat Rev Immunol. 2002;2(10):748–59. https://doi.org/10.1038/nri912

Xiao Q, He J, Lei A, Xu H, Zhang L, Zhou P, et al. PPARγ enhances ILC2 function during allergic airway inflammation via transcription regulation of ST2. Mucosal Immunol. 2021;14(2):468–78. https://doi.org/10.1038/s41385-020-00339-6

Symowski C, Voehringer D. Th2 cell‐derived IL‐4/IL‐13 promote ILC2 accumulation in the lung by ILC2‐intrinsic STAT6 signaling in mice. Eur J Immunol. 2019;49(9):1421–32. https://doi.org/10.1002/eji.201948161

Cui G, Shimba A, Jin J, Hojo N, Asahi T, Abe S, et al. CD45 alleviates airway inflammation and lung fibrosis by limiting expansion and activation of ILC2s. Proc Natl Acad Sci USA. 2023;120(36):e2215941120. https://doi.org/10.1073/pnas.2215941120

Snelgrove RJ, Goulding J, Didierlaurent AM, Lyonga D, Vekaria S, Edwards L, et al. A critical function for CD200 in lung immune homeostasis and the severity of influenza infection. Nat Immunol. 2008;9(9):1074–83. https://doi.org/10.1038/ni.1637

Casulli J, Fife ME, Houston SA, Rossi S, Dow J, Williamson ED, et al. CD200R deletion promotes a neutrophil niche for Francisella tularensis and increases infectious burden and mortality. Nat Commun. 2019;10(1):2121. https://doi.org/10.1038/s41467-019-10156-6

Liu JQ, Hu A, Zhu J, Yu J, Talebian F, Bai XF. CD200‐CD200R pathway in the regulation of tumor immune microenvironment and immunotherapy. Adv Exp Med Biol. 2020;1223:155–65. https://doi.org/10.1007/978-3-030-35582-1_8

Shafiei‐Jahani P, Helou DG, Hurrell BP, Howard E, Quach C, Painter JD, et al. CD200‐CD200R immune checkpoint engagement regulates ILC2 effector function and ameliorates lung inflammation in asthma. Nat Commun. 2021;12(1):2526. https://doi.org/10.1038/s41467-021-22832-7

Chiang EY, Mellman I. TIGIT‐CD226‐PVR axis: advancing immune checkpoint blockade for cancer immunotherapy. J Immunother Cancer. 2022;10(4):e004711. https://doi.org/10.1136/jitc-2022-004711

Sakano Y, Sakano K, Hurrell BP, Helou DG, Shafiei‐Jahani P, Kazemi MH, et al. Blocking CD226 regulates type 2 innate lymphoid cell effector function and alleviates airway hyperreactivity. J Allergy Clin Immunol. 2024;153(5):1406–22.e6. https://doi.org/10.1016/j.jaci.2024.01.003

Seillet C, Mielke LA, Amann‐Zalcenstein DB, Su S, Gao J, Almeida FF, et al. Deciphering the innate lymphoid cell transcriptional program. Cell Rep. 2016;17(2):436–47. https://doi.org/10.1016/j.celrep.2016.09.025

Yu Y, Tsang JCH, Wang C, Clare S, Wang J, Chen X, et al. Single‐cell RNA‐seq identifies a PD‐1hi ILC progenitor and defines its development pathway. Nature. 2016;539(7627):102–6. https://doi.org/10.1038/nature20105

Taylor S, Huang Y, Mallett G, Stathopoulou C, Felizardo TC, Sun MA, et al. PD‐1 regulates KLRG1⁺ group 2 innate lymphoid cells. J Exp Med. 2017;214(6):1663–78. https://doi.org/10.1084/jem.20161653

Helou DG, Shafiei‐Jahani P, Lo R, Howard E, Hurrell BP, Galle‐Treger L, et al. PD‐1 pathway regulates ILC2 metabolism and PD‐1 agonist treatment ameliorates airway hyperreactivity. Nat Commun. 2020;11(1):3998. https://doi.org/10.1038/s41467-020-17813-1

Cephus JY, Stier MT, Fuseini H, Yung JA, Toki S, Bloodworth MH, et al. Testosterone attenuates group 2 innate lymphoid cell‐mediated airway inflammation. Cell Rep. 2017;21(9):2487–99. https://doi.org/10.1016/j.celrep.2017.10.110

Blanquart E, Mandonnet A, Mars M, Cenac C, Anesi N, Mercier P, et al. Targeting androgen signaling in ILC2s protects from IL‐33–driven lung inflammation, independently of KLRG1. J Allergy Clin Immunol. 2022;149(1):237–51.e12. https://doi.org/10.1016/j.jaci.2021.04.029

Adams KL, Riparini G, Banerjee P, Breur M, Bugiani M, Gallo V. Endothelin‐1 signaling maintains glial progenitor proliferation in the postnatal subventricular zone. Nat Commun. 2020;11(1):2138. https://doi.org/10.1038/s41467-020-16028-8

Ford TJ, Corcoran D, Padmanabhan S, Aman A, Rocchiccioli P, Good R, et al. Genetic dysregulation of endothelin‐1 is implicated in coronary microvascular dysfunction. Eur Heart J. 2020;41(34):3239–52. https://doi.org/10.1093/eurheartj/ehz915

Belaidi E, Morand J, Gras E, Pépin JL, Godin‐Ribuot D. Targeting the ROS‐HIF‐1‐endothelin axis as a therapeutic approach for the treatment of obstructive sleep apnea‐related cardiovascular complications. Pharmacol Ther. 2016;168:1–11. https://doi.org/10.1016/j.pharmthera.2016.07.010

Kowalczyk A, Kleniewska P, Kolodziejczyk M, Skibska B, Goraca A. The role of endothelin‐1 and endothelin receptor antagonists in inflammatory response and sepsis. Arch Immunol Ther Exp. 2015;63(1):41–52. https://doi.org/10.1007/s00005-014-0310-1

Leask A. Potential therapeutic targets for cardiac fibrosis: TGFbeta, angiotensin, endothelin, CCN2, and PDGF, partners in fibroblast activation. Circ Res. 2010;106(11):1675–80. https://doi.org/10.1161/CIRCRESAHA.110.217737

Zhang X, Chen Z, Zuo S, Sun H, Li X, Lu X, et al. Endothelin‐A receptor antagonist alleviates allergic airway inflammation via the inhibition of ILC2 function. Front Immunol. 2022;13:835953. https://doi.org/10.3389/fimmu.2022.835953

Kawai T, Akira S. TLR signaling. Semin Immunol. 2007;19(1):24–32. https://doi.org/10.1016/j.smim.2006.12.004

Okuzumi S, Miyata J, Kabata H, Mochimaru T, Kagawa S, Masaki K, et al. TLR7 agonist suppresses group 2 innate lymphoid cell‐mediated inflammation via IL‐27‐producing interstitial macrophages. Am J Respir Cell Mol Biol. 2021;65(3):309–18. https://doi.org/10.1165/rcmb.2021-0042OC

Fu L, Zhao J, Huang J, Li N, Dong X, He Y, et al. A mitochondrial STAT3‐methionine metabolism axis promotes ILC2‐driven allergic lung inflammation. J Allergy Clin Immunol. 2022;149(6):2091–104. https://doi.org/10.1016/j.jaci.2021.12.783

Toki S, Goleniewska K, Reiss S, Zhou W, Newcomb DC, Bloodworth MH, et al. The histone deacetylase inhibitor trichostatin A suppresses murine innate allergic inflammation by blocking group 2 innate lymphoid cell (ILC2) activation. Thorax. 2016;71(7):633–45. https://doi.org/10.1136/thoraxjnl-2015-207728

Cahalan SM, Lukacs V, Ranade SS, Shu C, Bandell M, Patapoutian A. Piezo1 links mechanical forces to red blood cell volume. Elife. 2015;4:e07370. https://doi.org/10.7554/eLife.07370

Jia Q, Yang Y, Chen X, Yao S, Hu Z. Emerging roles of mechanosensitive ion channels in acute lung injury/acute respiratory distress syndrome. Respir Res. 2022;23(1):366. https://doi.org/10.1186/s12931-022-02303-3

Hurrell BP, Shen S, Li X, Sakano Y, Kazemi MH, Quach C, et al. Piezo1 channels restrain ILC2s and regulate the development of airway hyperreactivity. J Exp Med. 2024;221(5):e20231835. https://doi.org/10.1084/jem.20231835

Patel DF, Peiró T, Bruno N, Vuononvirta J, Akthar S, Puttur F, et al. Neutrophils restrain allergic airway inflammation by limiting ILC2 function and monocyte‐dendritic cell antigen presentation. Sci Immunol. 2019;4(41):eaax7006. https://doi.org/10.1126/sciimmunol.aax7006

Shimizu Y, Horigane‐Konakai Y, Ishii Y, Sugimoto C, Wakao H. Mucosal‐associated invariant T cells repress group 2 innate lymphoid cells in Alternaria alternata‐induced model of allergic airway inflammation. Front Immunol. 2022;13:1005226. https://doi.org/10.3389/fimmu.2022.1005226

Su HH, Cheng CM, Yang YN, Chang YW, Li CY, Wu ST, et al. Acrylamide, an air pollutant, enhances allergen‐induced eosinophilic lung inflammation via group 2 innate lymphoid cells. Mucosal Immunol. 2024;17(1):13–24. https://doi.org/10.1016/j.mucimm.2023.09.007

Alvaro‐Lozano M, Akdis CA, Akdis M, Alviani C, Angier E, Arasi S, et al. EAACI allergen immunotherapy user's guide. Pediatr Allergy Immunol. 2020;31(Suppl 25):1–101. https://doi.org/10.1111/pai.13189

Karakoc‐Aydiner E, Eifan AO, Baris S, Gunay E, Akturk E, Akkoc T, et al. Long‐term effect of sublingual and subcutaneous immunotherapy in dust mite‐allergic children with asthma/rhinitis: a 3‐year prospective randomized controlled trial. J Investig Allergol Clin Immunol. 2015;25(5):334–42.

Zielen S, Kardos P, Madonini E. Steroid‐sparing effects with allergen‐specific immunotherapy in children with asthma: a randomized controlled trial. J Allergy Clin Immunol. 2010;126(5):942–9. https://doi.org/10.1016/j.jaci.2010.06.002

Tanaka A, Tohda Y, Okamiya K, Azuma R, Terada I, Adachi M. Efficacy and safety of HDM SLIT tablet in Japanese adults with allergic asthma. J Allergy Clin Immunol Pract. 2020;8(2):710–20.e14. https://doi.org/10.1016/j.jaip.2019.09.002

Bush RK, Swenson C, Fahlberg B, Evans MD, Esch R, Morris M, et al. House dust mite sublingual immunotherapy: results of a US trial. J Allergy Clin Immunol. 2011;127(4):974–81. e1–7. https://doi.org/10.1016/j.jaci.2010.11.045

Radtke F, MacDonald HR, Tacchini‐Cottier F. Regulation of innate and adaptive immunity by Notch. Nat Rev Immunol. 2013;13(6):427–37. https://doi.org/10.1038/nri3445

Tong Y, Wang L, Wang L, Song J, Fan J, Lai C, et al. Allergen immunotherapy combined with Notch pathway inhibitors improves HDM‐induced allergic airway inflammation and inhibits ILC2 activation. Front Immunol. 2024;14:1264071. https://doi.org/10.3389/fimmu.2023.1264071

Kudo F, Ikutani M, Iseki M, Takaki S. Cyclosporin A indirectly attenuates activation of group 2 innate lymphoid cells in papain‐induced lung inflammation. Cell Immunol. 2018;323:33–40. https://doi.org/10.1016/j.cellimm.2017.10.010

Tomiaki C, Miyauchi K, Ki S, Suzuki Y, Suzuki N, Morimoto H, et al. Role of FK506‐sensitive signals in asthmatic lung inflammation. Front Immunol. 2022;13:1014462. https://doi.org/10.3389/fimmu.2022.1014462

McCracken GH, Jr. Etiology and treatment of pneumonia. Pediatr Infect Dis J. 2000;19(4):373–7. https://doi.org/10.1097/00006454-200004000-00032

Matsuyama T, Machida K, Motomura Y, Takagi K, Doutake Y, Tanoue‐Hamu A, et al. Long‐acting muscarinic antagonist regulates group 2 innate lymphoid cell‐dependent airway eosinophilic inflammation. Allergy. 2021;76(9):2785–96. https://doi.org/10.1111/all.14836

Gao F, Chiu SM, Motan DAL, Zhang Z, Chen L, Ji HL, et al. Mesenchymal stem cells and immunomodulation: current status and future prospects. Cell Death Dis. 2016;7(1):e2062. https://doi.org/10.1038/cddis.2015.327

Fang SB, Zhang HY, Jiang AY, Fan XL, Lin YD, Li CL, et al. Human iPSC‐MSCs prevent steroid‐resistant neutrophilic airway inflammation via modulating Th17 phenotypes. Stem Cell Res Ther. 2018;9(1):147. https://doi.org/10.1186/s13287-018-0897-y

Sun YQ, Deng MX, He J, Zeng QX, Wen W, Wong DSH, et al. Human pluripotent stem cell‐derived mesenchymal stem cells prevent allergic airway inflammation in mice. Stem Cell. 2012;30(12):2692–9. https://doi.org/10.1002/stem.1241

de Castro LL, Xisto DG, Kitoko JZ, Cruz FF, Olsen PC, Redondo PAG, et al. Human adipose tissue mesenchymal stromal cells and their extracellular vesicles act differentially on lung mechanics and inflammation in experimental allergic asthma. Stem Cell Res Ther. 2017;8(1):151. https://doi.org/10.1186/s13287-017-0600-8

Fang SB, Zhang HY, Wang C, He BX, Liu XQ, Meng XC, et al. Small extracellular vesicles derived from human mesenchymal stromal cells prevent group 2 innate lymphoid cell‐dominant allergic airway inflammation through delivery of miR‐146a‐5p. J Extracell Vesicles. 2020;9(1):1723260. https://doi.org/10.1080/20013078.2020.1723260

Kalincik T, Brown JWL, Robertson N, Willis M, Scolding N, Rice CM, et al. Treatment effectiveness of alemtuzumab compared with natalizumab, fingolimod, and interferon beta in relapsing‐remitting multiple sclerosis: a cohort study. Lancet Neurol. 2017;16(4):271–81. https://doi.org/10.1016/S1474-4422(17)30007-8

Shafiei‐Jahani P, Helou DG, Hurrell BP, Galle‐Treger L, Howard E, Quach C, et al. CD52‐targeted depletion by Alemtuzumab ameliorates allergic airway hyperreactivity and lung inflammation. Mucosal Immunol. 2021;14(4):899–911. https://doi.org/10.1038/s41385-021-00388-5

Vojdeman FJ, Herman SEM, Kirkby N, Wiestner A, van T' Veer MB, Tjønnfjord GE, et al. Soluble CD52 is an indicator of disease activity in chronic lymphocytic leukemia. Leuk Lymphoma. 2017;58(10):2356–62. https://doi.org/10.1080/10428194.2017.1285027

Ishizawa K, Fukuhara N, Nakaseko C, Chiba S, Ogura M, Okamoto A, et al. Safety, efficacy and pharmacokinetics of humanized anti‐CD52 monoclonal antibody alemtuzumab in Japanese patients with relapsed or refractory B‐cell chronic lymphocytic leukemia. Jpn J Clin Oncol. 2017;47(1):54–60. https://doi.org/10.1093/jjco/hyw146